Meeting Expectations with Steady Growth- Trend to Continue
Soliris uptake in patients for Paroxysmal Nocturnal Hemoglobinuria (PNH) and accelerated approval in atypical Hemolytic Uremic Syndrome (aHUS) validate the long term potential of the drug. In upcoming scientific conference American Society of Nephrology (Nov. 8th to 13th) ALXN will present multiple data, showing potential of eculizumab in other indications targeting rare and high unmet need along with approved indication… For more details, please read our report released on October 21, 2011 on Alexion (ALXN), titled “Meeting Expectations with Steady Growth- Trend to Continue”.
COMPANIES MENTIONED
Alexion, Biogen Idec, Celgene, Gilead
Alexion, Biogen Idec, Celgene, Gilead
More Publications
New Technologies Initiative: Gateway to Treating Genetic Diseases - Sarepta Therapeutics - Skipping Makes Sense - Restoring Muscle Function in Duchenne Muscular Dystrophy
US$ 500.00
March 2013
18 pages
VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!
US$ 90.00
October 2011
4 pages
HCV_M&A - “Mirror, Mirror on the Wall (HCV) – Who is the Fairest of them all!”
US$ 140.00
January 2012
6 pages
BMY, Eliquis Complete Response – Another disappointment from Late Stage pipeline for BMY
US$ 90.00
June 2012
1 pages
Enanta- It is just the beginning of good news
US$ 90.00
November 2013
2 pages
